NCT06874621 - VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Alzheimer's Disease (AD)

Interventions

DRUG

VY7523

VY7523 is a recombinant humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody targeting human pathological tau

DRUG

Placebo Comparator

Matching placebo to VY7523

Trial Locations (23)

19462

RECRUITING

VYGR Site 840011, Plymouth Meeting

28105

RECRUITING

VYGR Site 840009, Matthews

30030

RECRUITING

VYGR Site 840007, Decatur

32159

RECRUITING

VYGR Site 840010, Lady Lake

32162

RECRUITING

VYGR Site 840004, The Villages

32789

RECRUITING

VYGR Site 840020, Winter Park

32803

RECRUITING

VYGR Site 840006, Orlando

33126

RECRUITING

VYGR Site 840015, Miami

33135

RECRUITING

VYGR Site 840014, Miami

33137

RECRUITING

VYGR Site 840024, Miami

33414

RECRUITING

VYGR Site 840002, Wellington

33445

RECRUITING

VYGR Site 840005, Delray Beach

33912

RECRUITING

VYGR Site 840021, Fort Myers

34997

RECRUITING

VYGR Site 840003, Stuart

90033

RECRUITING

VYGR Site 840018, Los Angeles

92866

RECRUITING

VYGR Site 840016, Orange

94158

RECRUITING

VYGR Site 840022, San Francisco

06905

RECRUITING

VYGR Site 840008, Stamford

08755

RECRUITING

VYGR Site 840012, Toms River

K1Z1G3

RECRUITING

VYGR Site 124002, Ottawa

M3B2S7

RECRUITING

VYGR Site 124001, Toronto

H3G1H9

RECRUITING

VYGR Site 124003, Montreal

H4A3T2

RECRUITING

VYGR Site 124004, Montreal